Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback ...

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

However, its potential is seen as being tied to the ability of the drug to target the broader population of ESR1 'wild-type' patients While Pfizer trumpeted the result as a "clinically meaningful ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.

Pfizer CEO Albert Bourla said the drugmaker might move overseas manufacturing to its plants in the U.S. as Trump threatens ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

Pfizer is testing multiple doses for a once-a-day version of danuglipron after scrapping the development of a twice-daily version of the drug in late 2023. Pfizer said in January that it expects ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...